21,80 €
1,44 % heute
L&S, 12. Juni, 14:49 Uhr
ISIN
US14888U1016
Symbol
CPRX
Berichte
Sektor
Industrie

Catalyst Pharmaceuticals, Inc. Aktie News

Positiv
FXEmpire
ein Tag alt
Catalyst Pharmaceuticals, Inc. (CPRX), keeps growing, bringing in Big Money.
Neutral
GlobeNewsWire
10 Tage alt
Gary Ingenito, MD, PhD is retiring from Catalyst after a successful career Gary Ingenito, MD, PhD is retiring from Catalyst after a successful career
Positiv
Seeking Alpha
12 Tage alt
FIRDAPSE continues to drive strong performance, with Q1 2025 revenue and EPS both beating analyst expectations significantly. Catalyst reaffirmed its 2025 FIRDAPSE revenue guidance of $355–$360 million, projecting 15–20% annual growth going forward. The company has penetrated about 25% of the $1.2 billion LEMS market, with further upside as cancer-associated LEMS remains underdiagnosed.
Neutral
Investors Business Daily
24 Tage alt
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Neutral
Seeking Alpha
etwa ein Monat alt
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Michael Kalb - Executive Vice President & Chief Financial Officer Richard Daly - President and Chief Executive Officer Jeff Del Carmen - Executive Vice President, Chief Commercial Officer Steven Miller - Executive Vice President, Chief Operating Officer and Chief Scientific...
Neutral
GlobeNewsWire
etwa ein Monat alt
Catalyst Enters 2025 With Strong Momentum; Reiterates Confidence in Full-Year Outlook Delivers Record Q1 2025 Total Revenues of $141.4 Million, a 43.6% YoY Increase FIRDAPSE® and AGAMREE® Drive Sustained Organic Growth, Underscoring Execution Strength Reaffirms Full-Year 2025 Total Revenue Guidance Provided Earlier This Year  of Between $545 Million and $565 Million Strengthens Balance Sheet wi...
Neutral
GlobeNewsWire
etwa ein Monat alt
CORAL GABLES, Fla., April 30, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that Richard J. Daly, President and CEO of Catalyst, along with other me...
Neutral
GlobeNewsWire
etwa 2 Monate alt
The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ET The Company will Host a Conference Call and Webcast on May 8, 2025, at 8:30 AM ET

Kostenlos registrieren

aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.

Die Apple Aktie im Überblick mit Charts, aktuellen Kennzahlen, Nachrichten und Aktienanalysen.
Die besten Dividenden-Aktien in der Dividenden-Topscorer-Liste.
Aktienanalysen der besten Aktien weltweit.
Jetzt Vermögen aufbauen